Welcome to the Cannabis Countdown. In This Week’s Edition, We Recap and Countdown the Top 10 Marijuana and Psychedelic Stock News Stories for the Week of December 28th, 2020 – January 3rd, 2021.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view the full article.
10. Horizons ETFs Rebalances Canadian and U.S. Cannabis ETFs, Here’s How Both ETFs Performed in 2020
Following Horizons’ Quarterly Rebalance, Here’s What the Top 10 Holdings of Their HMMJ and HMUS Cannabis ETFs Look Like Now
On December 29, 2020, Horizons ETFs Management (Canada) announced it completed a quarterly rebalance of the holdings of its two Cannabis ETFs: Horizons Marijuana Life Sciences Index ETF HMMJ and the Horizons U.S. Marijuana Index ETF HMUS.
READ FULL CANNABIS ETFS ARTICLE
9. 2020: A Year In Review For The Psychedelic Renaissance
Psychedelics Are Winning Big With Major Players Drawing Serious Investment Interest
Money tends to follow efficacy in biotech and pharmaceutical investing, and psychedelics have certainly exhibited incredible efficacy. Indeed, 2020 has witnessed several Psychedelics IPO, crazy stock surges and some major financings. MindMed MMEDF recently closed an upsized $80 million bought deal and Silicon Valley billionaire Peter Thiel-backed psychedelic pioneers, Compass Pathways CMPS, were the first psychedelic company to debut on the NASDAQ this year.
READ FULL 2020 PSYCHEDELICS ARTICLE
8. Aphria CEO Talks Up Tilray Deal, Expects to Be EBIDTA-Positive and ‘Not Burning Cash’
It is Estimated the Combined Entity Will Be Valued at Roughly $3.9 Billion, Boasting Pro-Forma Yearly Sales of $685 Million
Earlier this month, cannabis growers Aphria APHA and Tilray TLRY announced a merger to create the largest enterprise in the industry by revenue. Aphria recently acquired SweetWater Brewing Company for $300 million. Tilray, meanwhile, has a joint venture with Anheuser-Busch InBev BUD called Fluent Beverage Company. Both these relationships signal a clear interest from the companies in the beverage space.
7. How Will Psychedelics Become Medicine? A Scientific Review of the Drug Development Pathway
The Drug Discovery and Development Pipeline Can Take Up to 15 Years to Complete and Even Then, Only 14% of Drugs That Make it to Their Respective Clinical Trials Will Gain Regulatory Approval and a Large Amount of Money is Spent Either Way
The regulatory restrictions behind the high cost and high failure rate of drug approvals also apply to the emerging Psychedelic medicine industry. However, innovators at MagicMed Industries have significantly de-risked this process for stakeholders of psychedelic medicine. Through its unique approach to psychedelic drug development, MagicMed has addressed many of these aforementioned problems.
6. Ayr Strategies is One of Our Top Picks, Says Echelon Capital Markets
It’s Been a Busy Month for Ayr Strategies, Which Has Operations in Nevada and Massachusetts Including 3 Cultivation and Processing Facilities Along with 7 Cannabis Dispensaries Across the 2 States
Echelon analyst Andrew Semple likes the looks of two new acquisitions by cannabis company Ayr Strategies AYRSF. In an update to clients on December 23, Semple reiterated his “Buy” rating while raising his target price from C$43.00 to C$53.00, which represented at press time a projected 12-month return of 90.3%.
5. NeonMind, the Company Researching Psilocybin for Weight Loss, Approved for Listing on the CSE
Neonmind, a Subsidiary of Vancouver-Based Health and Wellness Firm Better Plant Sciences, Will Begin Trading on the Canadian Securities Exchange on Monday
Better Plant Sciences VEGGF announced this morning that its partially owned subsidiary Neonmind expects to close its initial public offering tomorrow, on December 30. Trading will kick off on the CSE on January 4 under the stock ticker symbol “NEON”. This will not affect Better Plant Sciences, which will continue to trade on the CSE and OTC under its existing symbols.
4. Needham Names Green Thumb Industries, Ayr Strategies as 2021 Top Picks
Needham & Company Released a 2021 Outlook Wherein They Named Ayr Strategies and Green Thumb Industries as Their Top Picks for 2021
Matt McGinly, Needham’s analyst, currently has a US$28 (C$35.64) 12-month price target on Ayr Strategies AYRSF. This compares to the C$44.25 average price target, which has risen from C$33.50 in the last month. His current Green Thumb GTBIF price target is C$39, while the average analyst price target is C$36.92, up slightly since last month.
3. Big Pharma is About to Tune in to the Potential of Psychedelics
Psychedelic Medicine Will Begin to Cross Over Into the Mental Health Mainstream in 2021
In both Europe and the US, medicines regulators have eased restrictions on using MDMA to treat PTSD, and on Psilocybin – the active substance in Magic Mushrooms – to treat depression. In the UK, London-based mental-health care company Compass Pathways CMPS has raised more than $115m to fund its efforts and bring to market a psilocybin treatment for depression. In August, the company filed an application to issue an IPO on the NASDAQ.
2. What if Canopy Growth Acquired Village Farms?
Consolidation Continues in the Burgeoning North American Cannabis Market and There’s One Deal That Makes a Lot of Sense
Raymond James analyst Rahul Sarugaser says a merger between Canopy Growth CGC and Village Farms VFF would be that one deal. In a company brief to clients on December 24, Sarugaser reiterated his “Strong Buy 1” for Village Farms while making the case for the acquisition.
1. Horizons to Launch World’s First Psychedelic Stock Index ETF
On December 24, the Psychedelics Sector Received an Early Christmas Present
Horizons ETFs filed a prospectus to introduce the world’s first Psychedelic Stock ETF to the market. The soon-to-be NEO Exchange-listed issue is a natural extension of a sector that has come of age—specifically in the calendar fourth quarter of this year. The Horizons Psychedelic Stock ETF could be a great way for investors to gain exposure while decentralizing risk.
READ FULL PSYCHEDELICS ETF ARTICLE
Photo by Drew Taylor on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.